Bromopride
As of the edition of 20 October 2026, Bromopride is a small molecule: marketed, first approved in 2023 (BR); acts on DRD2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Small molecule
- Brand name
- Digesan
- First approved
- 10 July 2023 (BR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Eurofarma Laboratorios
- Registered trials
- 1, 0 stopped early
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| DRD2 | Dopamine receptor D2 | P14416 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Eurofarma Laboratorios | Applicant | 2023 to now |